​

Annovis Bio (ANVS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ANVS Stock Forecast

Annovis Bio (ANVS) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $25.67, with a high of $30.00 and a low of $21.00. This represents a 2004.10% increase from the last price of $1.22.

- $6 $12 $18 $24 $30 High: $30 Avg: $25.67 Low: $21 Last Closed Price: $1.22

ANVS Stock Rating

Annovis Bio stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (75.00%), 2 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 6 Strong Sell Sell Hold Buy Strong Buy

ANVS Price Target Upside V Benchmarks

TypeNameUpside
StockAnnovis Bio2004.10%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$25.67
Last Closing Price$1.22$1.22$1.22
Upside/Downside--2004.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25232--7
Mar, 25241--7
Feb, 25231--6
Jan, 25231--6
Dec, 24231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2024Raghuram SelvarajuH.C. Wainwright$30.00$8.82240.14%2359.02%
Aug 13, 2024Jason KolbertEF Hutton$21.00$7.87166.84%1621.31%
Apr 30, 2024Sumant KulkarniCanaccord Genuity$26.00$7.28257.14%2031.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024Canaccord GenuityBuyBuyhold
Aug 13, 2024EF HuttonBuyinitialise
Jul 11, 2024H.C. WainwrightBuyBuyhold
Jul 02, 2024Rodman & RenshawBuyBuyhold
Jun 04, 2024Rodman & RenshawBuyinitialise

Financial Forecast

EPS Forecast

$-3K $-2K $-2K $-1K $-500 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.23$-2.02K----
Avg Forecast$-5.65$-1.93$-1.86$-1.77$-2.65$-1.51
High Forecast$-5.51$-1.73$-1.15$-0.58$-0.56$-1.51
Low Forecast$-5.96$-2.13$-2.55$-2.76$-5.58$-1.51
Surprise %10.27%104485.49%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$10.95M$206.36M$70.60M
High Forecast---$10.95M$206.36M$70.60M
Low Forecast---$10.95M$206.36M$70.60M
Surprise %------

Net Income Forecast

$-25B $-20B $-15B $-10B $-5B $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-56.20M$-24.59B----
Avg Forecast$-51.73M$-17.40M$-16.70M$-15.05M$-27.71M$-13.59M
High Forecast$-49.72M$-15.61M$-10.40M$-5.21M$-5.04M$-13.59M
Low Forecast$-53.74M$-19.20M$-22.99M$-24.89M$-50.39M$-13.59M
Surprise %8.65%141184.10%----

ANVS Forecast FAQ

Is Annovis Bio stock a buy?

Annovis Bio stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Annovis Bio is a favorable investment for most analysts.

What is Annovis Bio's price target?

Annovis Bio's price target, set by 8 Wall Street analysts, averages $25.67 over the next 12 months. The price target range spans from $21 at the low end to $30 at the high end, suggesting a potential 2004.10% change from the previous closing price of $1.22.

How does Annovis Bio stock forecast compare to its benchmarks?

Annovis Bio's stock forecast shows a 2004.10% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Annovis Bio over the past three months?

  • April 2025: 28.57% Strong Buy, 42.86% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Annovis Bio’s EPS forecast?

Annovis Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.86, marking a -99.91% decrease from the reported $-2.018K in 2024. Estimates for the following years are $-1.77 in 2026, $-2.65 in 2027, and $-1.51 in 2028.

What is Annovis Bio’s revenue forecast?

Annovis Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10.95M, followed by $206.36M for 2027, and $70.6M for 2028.

What is Annovis Bio’s net income forecast?

Annovis Bio's net income forecast for the fiscal year ending in December 2025 stands at $-16.697M, representing a -99.93% decrease from the reported $-24.59B in 2024. Projections indicate $-15.05M in 2026, $-27.713M in 2027, and $-13.595M in 2028.